ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
MYGN Description — Myriad Genetics, Inc.

Myriad Genetics is a molecular diagnostic company that develops and markets predictive medicine, personalized medicine and prognostic medicine tests. Co.'s commercial molecular diagnostic tests are myRisk Hereditary Cancer for cancers, BRACAnalysis® and BART® for breast and ovarian cancer, BRACAnalysis CDx for ovarian cancer, Tumor BRACAnalysis CDx, COLARIS® and COLARIS AP® for colorectal and uterine cancer, Vectra®DA, Prolaris® for prostate cancer, EndoPredict®, myPath Melanoma, and myPlan Lung Cancer. Through its Myriad RBM, Inc. subsidiary, Co. provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries.

Company Name:  Myriad Genetics, Inc.
Website:  www.myriad.com
Sector:  Biotechnology
Number of ETFs Holding MYGN:  30
Total Market Value Held by ETFs:  $157,139,225.48
Total Market Capitalization:  $2,370,000,000
% of Market Cap. Held by ETFs:  6.63%
 ETF   MYGN Weight   MYGN Amount 
 IWM   0.15%   $36,175,780         
 IBB   0.46%   $31,203,229         
 XBI   1.63%   $28,283,701         
 FBT   3.29%   $26,598,128         
 IWO   0.31%   $17,520,691         
 PBE   2.60%   $6,658,828         
 XT   0.43%   $2,939,803         
 BIB   0.42%   $1,783,784         
 IYH   0.09%   $1,596,162         
 PRFZ   0.09%   $947,052         
List of all 30 ETFs holding MYGN »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
Top 10 Analyst Rated Consumer Stocks
Top 10 Analyst Rated Dividend Stocks
Top 10 Analyst Rated Energy Stocks
Top 10 Analyst Rated Financial Stocks
Top 10 Analyst Rated Healthcare Stocks
Top 10 Analyst Rated REIT Stocks
Top 10 Analyst Rated Technology Stocks
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Buy (2.62 out of 4)
25th percentile
(ranked lower than approx. 75% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Tue, May 17, 6:04 AM, Zacks
Myriad Genetics Brings myVectra Web Portal for RA Patients
Myriad's (MYGN) myVectra portal will offer easy access for its users to their Vectra DA test score, which in turn would keep the concerned RA patients better informed about the current status of their disease.

Mon, May 16, 6:06 AM, Zacks
Myriad Genetics: Test Revenues Strong, Currency Woes Stay
Myriad (MYGN) ended the third quarter of fiscal 2016 on a promising note, beating the Zacks Consensus Estimate on both top and bottom-line fronts

ETFs Holding MYGN | Myriad Genetics, Inc. | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2016, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.